Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A validated mathematical model of FGFR3‐mediated tumor growth reveals pathways to harness the benefits of combination targeted therapy and immunotherapy in bladder cancer

Computational and Systems Oncology(2021)10.1002/cso2.1019Source: DataRank Database

A validated mathematical model of FGFR3‐mediated tumor growth reveals pathways to harness the benefits of combination targeted therapy and immunotherapy in bladder cancer is a research paper published in Computational and Systems Oncology (2021). On theSindex it has a DataRank of 0. It has been cited 17 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access17 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 2.63)OA: goldTopics (22)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Daniel Bergman ORCID,Jeffrey Bloodworth,Alexander T. Pearson ORCID,Randy F. Sweis ORCID,Trachette L. Jackson ORCID

Live enrichment

PubMed:34984415 PMC:PMC8722426 OpenAlex:https://openalex.org/W3165651406

National Institutes of Health

Grant: U01CA243075

National Institutes of Health

Grant: K08 CA234392

FWCI

2.63

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://doi.org/10.1002/cso2.1019

publisherhttps://doi.org/10.1002/cso2.1019

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/cso2.1019

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/cso2.1019

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34984415

Fields of Study

Bladder and Urothelial Cancer TreatmentsFibroblast Growth Factor ResearchRenal cell carcinoma treatment

Keywords

MedicineImmunotherapyBladder cancerOncologyTargeted therapyReceptor tyrosine kinaseImmune checkpointMalignancyCancerCancer researchTyrosine-kinase inhibitorMonoclonal antibodyInternal medicineImmunologyAntibodyReceptormathematical modelImmune Checkpoint InhibitorsFgfr3-targeted Therapy

Sustainable Development Goals

SDG 0: Good health and well-being